Recommendation of the President – Tagrisso (osimertinib)

On 24 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 46/2025 on the appraisal of drug Tagrisso (osimertinib) in the B.6. drug program. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication in Public Information Bulletin (BIP) >>